Treatment of acute pelvic inflammatory disease with aztreonam, a new monocyclic beta-lactam antibiotic, and clindamycin.
Forty-two patients with acute pelvic inflammatory disease were treated using aztreonam, a monobactam, and clindamycin. Sixty-four percent of protocol patients were culture positive for Neisseria gonorrhoeae, and 26% had positive endometrial cultures for other organisms. Fifty-one percent of patients had ultrasound findings consistent with a pelvic abscess. One patient with a tuboovarian abscess palpable to the umbilicus became afebrile and improved on treatment, but ultimately was treated surgically. All other protocol patients responded rapidly to the aztreonam-clindamycin regime, giving a 97.7% cure rate.
Dodson
M G
MG
Faro
S
S
Gentry
L O
LO
D000328:Adult; D001398:Aztreonam / Q000008:administration & dosage* / Q000627:therapeutic use; D001831:Body Temperature / Q000187:drug effects; D002584:Cervix Uteri / Q000187:drug effects / Q000382:microbiology; D002981:Clindamycin / Q000008:administration & dosage* / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004717:Endometrium / Q000187:drug effects / Q000382:microbiology; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008111:Liver Function Tests; D009344:Neisseria gonorrhoeae / Q000302:isolation & purification; D010146:Pain / Q000188:drug therapy; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy*
D002981:Clindamycin; D001398:Aztreonam